Text Size
14 studies found for:    omalizumab, urticaria

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
Conditions: Chronic Urticaria;   Chronic Idiopathic Urticaria;   Chronic Spontaneous Urticaria
Interventions: Drug: Omalizumab (Xolair);   Drug: Placebo
2 Completed
Has Results 		Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Omalizumab 75-375 mg;   Drug: Placebo to omalizumab;   Drug: Loratadine;   Drug: Clemastine
3 Recruiting Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Biological: Omalizumab;   Biological: Placebo
4 Recruiting Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: IGE025;   Drug: placebo
5 Completed
Has Results 		A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: omalizumab;   Drug: placebo;   Drug: H1 antihistamines;   Drug: Diphenhydramine
6 Not yet recruiting Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
Condition: Chronic Urticaria
Intervention: Drug: Omalizumab
7 Recruiting Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
8 Completed A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: omalizumab;   Drug: placebo
9 Recruiting Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Conditions: Diagnosis of Chronic Spontaneous Urticaria (CSU) Refractory to H1-antihistamine Treatment;   Presence of Itch an Hives for More Than 6 Weeks;   UAS7 Score of More Than 14 (Range 0-42);   Patient Has History of Insufficient Response to 4x of the Approved Dose of H1-antihistamines;   CSU Diagnosis for More Than 6 Months;   Angioedema at Least 4x in the Last 6 Months
Interventions: Biological: Omalizumab;   Drug: Placebo
10 Active, not recruiting A Study of the Efficacy and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: omalizumab;   Drug: placebo
11 Active, not recruiting A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: omalizumab;   Drug: placebo
12 Completed Effect of Anti-IgE in Chronic Urticaria
Condition: Urticaria
Intervention: Drug: Xolair® (Omalizumab)
13 Recruiting The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Condition: Mastocytosis
Intervention: Drug: injections
14 Recruiting A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Conditions: Anaphylaxis;   Hypotension;   Bronchospasm;   Angioedema
Interventions: Drug: Epinephrine;   Procedure: Bone Marrow Apsiration;   Drug: Omalizumab (Xolair)
To Top

† Indicates status has not been verified in more than two years